Menu

Chemist Sues University Again

Suvi Orr has filed suit against the University of Texas for the second time in two years in an attempt to prevent the school from revoking her PhD.

Feb 11, 2016
Jef Akst

FLICKR, DEREK KEYIn 2014, Pfizer chemist Suvi Orr sued the University of Texas at Austin, where she had earned her PhD in 2008, after the school pulled her degree due to the “falsified and misreported data” included in her dissertation. Now, according to a lawsuit filed last week (February 4) in state District Court in Travis County, the university is once again trying to revoke her degree, and Orr is once again suing to prevent the disciplinary action.

“Although the lawsuit refers to the plaintiff by those initials for privacy protections under federal law, the circumstances of the case leave no doubt that she is Orr,” the Austin American-Statesman reported.

Orr contends that she is being held accountable for the mistakes of her former advisor, University of Texas chemist Stephen Martin; both were authors on an Organic Letters paper that was retracted in 2011 after the chemical synthesis was unable to be reproduced, Retraction Watch reported this week (February 9). According to the latest suit, the school will hold a hearing next month in which three undergraduate students and two faculty members will deliberate on Orr’s case, but the suit argues that none of them “are qualified to evaluate the scientific evidence being used against S.O.” According to the Statesman, a hearing has been scheduled for next week (February 17) in response to Orr’s request to stop the proceedings.

“The University should not be permitted to so cavalierly attempt to take it away. S.O’s scientific career—and her livelihood—hinge on how a panel of undergraduate students review and interpret highly complex scientific data at the doctoral and postdoctoral level in organic chemistry,” the suit reads. 

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.